196 related articles for article (PubMed ID: 32868847)
1. Modulation of arousal and sleep/wake architecture by M
Gould RW; Russell JK; Nedelcovych MT; Bubser M; Blobaum AL; Bridges TM; Newhouse PA; Lindsley CW; Conn PJ; Nader MA; Jones CK
Neuropsychopharmacology; 2020 Dec; 45(13):2219-2228. PubMed ID: 32868847
[TBL] [Abstract][Full Text] [Related]
2. M
Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
[TBL] [Abstract][Full Text] [Related]
3. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.
Gould RW; Nedelcovych MT; Gong X; Tsai E; Bubser M; Bridges TM; Wood MR; Duggan ME; Brandon NJ; Dunlop J; Wood MW; Ivarsson M; Noetzel MJ; Daniels JS; Niswender CM; Lindsley CW; Conn PJ; Jones CK
Neuropharmacology; 2016 Mar; 102():244-53. PubMed ID: 26617071
[TBL] [Abstract][Full Text] [Related]
4. M
Hassani SA; Neumann A; Russell J; Jones CK; Womelsdorf T
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2216792120. PubMed ID: 37104474
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
[TBL] [Abstract][Full Text] [Related]
6. M
Moran SP; Dickerson JW; Cho HP; Xiang Z; Maksymetz J; Remke DH; Lv X; Doyle CA; Rajan DH; Niswender CM; Engers DW; Lindsley CW; Rook JM; Conn PJ
Neuropsychopharmacology; 2018 Jul; 43(8):1763-1771. PubMed ID: 29581537
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M
van der Westhuizen ET; Spathis A; Khajehali E; Jörg M; Mistry SN; Capuano B; Tobin AB; Sexton PM; Scammells PJ; Valant C; Christopoulos A
Mol Pharmacol; 2018 Jul; 94(1):770-783. PubMed ID: 29691279
[TBL] [Abstract][Full Text] [Related]
8. Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration.
Panarese JD; Cho HP; Adams JJ; Nance KD; Garcia-Barrantes PM; Chang S; Morrison RD; Blobaum AL; Niswender CM; Stauffer SR; Conn PJ; Lindsley CW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3822-5. PubMed ID: 27173801
[TBL] [Abstract][Full Text] [Related]
9. Diverse Effects on M
Rook JM; Abe M; Cho HP; Nance KD; Luscombe VB; Adams JJ; Dickerson JW; Remke DH; Garcia-Barrantes PM; Engers DW; Engers JL; Chang S; Foster JJ; Blobaum AL; Niswender CM; Jones CK; Conn PJ; Lindsley CW
ACS Chem Neurosci; 2017 Apr; 8(4):866-883. PubMed ID: 28001356
[TBL] [Abstract][Full Text] [Related]
10. A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice.
Abd-Elrahman KS; Sarasija S; Colson TL; Ferguson SSG
Br J Pharmacol; 2022 Apr; 179(8):1769-1783. PubMed ID: 34820835
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of γ- and δ-Lactam M
Davoren JE; Garnsey M; Pettersen B; Brodney MA; Edgerton JR; Fortin JP; Grimwood S; Harris AR; Jenkinson S; Kenakin T; Lazzaro JT; Lee CW; Lotarski SM; Nottebaum L; O'Neil SV; Popiolek M; Ramsey S; Steyn SJ; Thorn CA; Zhang L; Webb D
J Med Chem; 2017 Aug; 60(15):6649-6663. PubMed ID: 28598634
[TBL] [Abstract][Full Text] [Related]
12. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel class of heteroaryl-pyrrolidinones as positive allosteric modulators of the muscarinic acetylcholine receptor M
Spearing PK; Cho HP; Luscombe VB; Blobaum AL; Boutaud O; Engers DW; Rodriguez AL; Niswender CM; Jeffrey Conn P; Lindsley CW; Bender AM
Bioorg Med Chem Lett; 2021 Sep; 47():128193. PubMed ID: 34118412
[TBL] [Abstract][Full Text] [Related]
14. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Scarpa M; Hesse S; Bradley SJ
Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
[TBL] [Abstract][Full Text] [Related]
15. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.
Ma L; Seager MA; Wittmann M; Jacobson M; Bickel D; Burno M; Jones K; Graufelds VK; Xu G; Pearson M; McCampbell A; Gaspar R; Shughrue P; Danziger A; Regan C; Flick R; Pascarella D; Garson S; Doran S; Kreatsoulas C; Veng L; Lindsley CW; Shipe W; Kuduk S; Sur C; Kinney G; Seabrook GR; Ray WJ
Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15950-5. PubMed ID: 19717450
[TBL] [Abstract][Full Text] [Related]
16. A Novel M
Rook JM; Bertron JL; Cho HP; Garcia-Barrantes PM; Moran SP; Maksymetz JT; Nance KD; Dickerson JW; Remke DH; Chang S; Harp JM; Blobaum AL; Niswender CM; Jones CK; Stauffer SR; Conn PJ; Lindsley CW
ACS Chem Neurosci; 2018 Sep; 9(9):2274-2285. PubMed ID: 29701957
[TBL] [Abstract][Full Text] [Related]
17. M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.
Bradley SJ; Bourgognon JM; Sanger HE; Verity N; Mogg AJ; White DJ; Butcher AJ; Moreno JA; Molloy C; Macedo-Hatch T; Edwards JM; Wess J; Pawlak R; Read DJ; Sexton PM; Broad LM; Steinert JR; Mallucci GR; Christopoulos A; Felder CC; Tobin AB
J Clin Invest; 2017 Feb; 127(2):487-499. PubMed ID: 27991860
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model.
Ghoshal A; Rook JM; Dickerson JW; Roop GN; Morrison RD; Jalan-Sakrikar N; Lamsal A; Noetzel MJ; Poslusney MS; Wood MR; Melancon BJ; Stauffer SR; Xiang Z; Daniels JS; Niswender CM; Jones CK; Lindsley CW; Conn PJ
Neuropsychopharmacology; 2016 Jan; 41(2):598-610. PubMed ID: 26108886
[TBL] [Abstract][Full Text] [Related]
19. TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys.
Kurimoto E; Nakashima M; Kimura H; Suzuki M
PLoS One; 2019; 14(3):e0207969. PubMed ID: 30856192
[TBL] [Abstract][Full Text] [Related]
20. Restoring Agonist Function at a Chemogenetically Modified M
Khajehali E; Bradley S; van der Westhuizen ET; Molloy C; Valant C; Finlayson L; Lindsley CW; Sexton PM; Tobin AB; Christopoulos A
ACS Chem Neurosci; 2020 Dec; 11(24):4270-4279. PubMed ID: 33196174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
